{"id":5771,"date":"2025-11-17T21:14:43","date_gmt":"2025-11-18T04:14:43","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=5771"},"modified":"2025-12-10T20:04:36","modified_gmt":"2025-12-11T03:04:36","slug":"tacicepts-vying-for-your-attention","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","title":{"rendered":"TACICEPTS VYING FOR YOUR ATTENTION"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Two posters on tacicepts caught our eyes.<\/p>\n\n\n\n

First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients with a 240 mg dose; both arms are dosed SC q4w.[1]<\/a><\/p>\n\n\n\n

Given the small patient cohort, open study design and absence of a placebo arm, this is just a first glimpse at efficacy. As it was a late-breaker, nobody bothered to check for typos either.<\/p>\n\n\n\n

We are told that the GFR ‘stabilized’; UPCR, hematuria and Gd-IgA1 levels were reduced. These early data confirm what we already know about the class of BAFF\/APRIL inhibitors; namely, that povetacicept does well on all accounts.  It is too early to make any quantitative comparisons or claims.  No need to update our tacicept comparison table from a prior blog yet, as we are only tracking pivotal Phase 3 trials. We are puzzled, however, by the lack of a dose response despite the 3-fold difference in dosing regimens.<\/p>\n\n\n\n

We interpret these data as a signal or trend in the right direction.<\/p>\n\n\n\n

Second, the Lafayette poster is about the atacicept ORIGIN-3 study, labeled correctly a “High-Impact Clinical Trial”.[2]<\/a>  Here, dosing was150 mg SC weekly.  The 36-wk results are indeed impressive but wait, where are the new data?  Could this be a duplicate publication?<\/p>\n\n\n

\n
\"\"<\/a>
ORIGIN-3 IA – From: Lafayette JASN<\/figcaption><\/figure>\n<\/div>\n\n\n

A recent NEJM article by Lafayette and the Vera team provided outcome information on the same population, now with graphs stacked vertically [3]<\/a>:<\/p>\n\n\n

\n
\"\"<\/a>
ORIGIN-3 IA – From: Lafayette NEJM<\/figcaption><\/figure>\n<\/div>\n\n\n

While the data for UPCR and Gd-IgA1 reductions are identical, we noticed some subtle changes to the hematuria graph: atacicept no longer comes out at -81.0% but at -82.1%, while hematuria in the placebo arm now shows a  -19.4% reduction, somewhat less than the -20.7% quoted in the (earlier) NEJM article.  Of note, the odds ratios are nevertheless unchanged.<\/p>\n\n\n\n

Both graphs and publications deal with the same IA of 203 patients (atacicept N=106; placebo N=97) at Week 36.  Why this difference?<\/p>\n\n\n\n

Usually, we are not sticklers about a 1-2% deviation in results from an IA, and neither should you be. Data correction of a single patient outcome may account for such small discrepancies. What seems like a duplicate publication is probably meant to be an update, a correction of sorts, to a secondary endpoint.<\/p>\n\n\n\n

This is, however, more than a routine IA. This data set with UPCR reduction at 36-wk as the primary efficacy outcome for ORIGIN-3 is at the core of Vera\u2019s FDA submission. The 203-patient FAS that constitutes the IA should be rock-solid by now (see timeline of primary study completion) and we should be told which graph is correct.<\/p>\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

The Vera team is now compiling the atacicept NDA dossier.  We are anxious to learn the final results.<\/p>\n\n\n\n

ABBREVIATIONS
<\/strong>Gd-IgA1        galactose-deficient IgA1
IA                   interim analysis
FAS               full analysis set
UPCR           urinary protein to creatinine ratio<\/p>\n\n\n\n

REFERENCES
<\/strong>[1]<\/a> Tumlin J.  Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study.  SA-OR091.  JASN 36(10S):10.1681\/ASN.20253s04myx7, October 2025
[2]<\/a> Lafayette R.  ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN.  TH-OR083JASN (10S):10.1681\/ASN.202589fw4b2p, October 2025.
[3]<\/a> Lafayette R.  A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.  NEJM. 2025 Nov 6. doi: 10.1056\/NEJMoa2510198.<\/p>\n","protected":false},"excerpt":{"rendered":"

Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":5781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[227,3,18],"tags":[1271,2209,2529,2531,2532,2194,2533,2408,2530,1583,2211,2212,2536,2210,2229,2208,2230,2534,2226],"class_list":["post-5771","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-allphase-pharma-consulting","tag-atacicept","tag-baff-april-inhibitors","tag-comparison-of-phase-3-trials","tag-competition-in-igan","tag-data-cleaning","tag-efficacy-comparison-of-tacicepts","tag-fcrn-inhibitors","tag-fda-endpoints","tag-harald-reinhart","tag-iga-nephropathy","tag-igan","tag-origin-trial","tag-povetacicept","tag-proteinuria","tag-telitacicept","tag-upcr","tag-vera-pharma","tag-vertex"],"yoast_head":"\nTACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC\" \/>\n<meta property=\"og:description\" content=\"Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION→\" \/>\n<meta property=\"og:url\" content=\"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/\" \/>\n<meta property=\"og:site_name\" content=\"Allphase Pharma Consulting, LLC\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T04:14:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T03:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Harald\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Harald\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/\"},\"author\":{\"name\":\"Harald\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#\\\/schema\\\/person\\\/b577474473153b47f4bf5b4cc676a2ee\"},\"headline\":\"TACICEPTS VYING FOR YOUR ATTENTION\",\"datePublished\":\"2025-11-18T04:14:43+00:00\",\"dateModified\":\"2025-12-11T03:04:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/\"},\"wordCount\":604,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1\",\"keywords\":[\"Allphase Pharma Consulting\",\"atacicept\",\"BAFF\\\/APRIL inhibitors\",\"comparison of Phase 3 trials\",\"competition in IgAN\",\"data cleaning\",\"efficacy comparison of tacicepts\",\"FcRn inhibitors\",\"FDA endpoints\",\"Harald Reinhart\",\"IgA nephropathy\",\"IgAN\",\"ORIGIN trial\",\"povetacicept\",\"proteinuria\",\"telitacicept\",\"UPCR\",\"VERA Pharma\",\"Vertex\"],\"articleSection\":[\"Recent Literature\",\"The News\",\"The Viewpoint\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/\",\"url\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/\",\"name\":\"TACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1\",\"datePublished\":\"2025-11-18T04:14:43+00:00\",\"dateModified\":\"2025-12-11T03:04:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1\",\"width\":2560,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/2025\\\/11\\\/17\\\/5771\\\/tacicepts-vying-for-your-attention\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TACICEPTS VYING FOR YOUR ATTENTION\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#website\",\"url\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/\",\"name\":\"Allphase Pharma Consulting, LLC\",\"description\":\"A Professional Service Provider for the Pharma Industry\",\"publisher\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#organization\",\"name\":\"Allphase Pharma Consulting, LLC\",\"url\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2017\\\/01\\\/LLC-Logo-300x125.jpg?fit=300%2C125&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/allphasepharma.com\\\/dir\\\/wp-content\\\/uploads\\\/2017\\\/01\\\/LLC-Logo-300x125.jpg?fit=300%2C125&ssl=1\",\"width\":300,\"height\":125,\"caption\":\"Allphase Pharma Consulting, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/#\\\/schema\\\/person\\\/b577474473153b47f4bf5b4cc676a2ee\",\"name\":\"Harald\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g\",\"caption\":\"Harald\"},\"sameAs\":[\"http:\\\/\\\/www.allphasepharma.com\"],\"url\":\"https:\\\/\\\/allphasepharma.com\\\/dir\\\/author\\\/haraldeva\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","og_locale":"en_US","og_type":"article","og_title":"TACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC","og_description":"Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION→","og_url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","og_site_name":"Allphase Pharma Consulting, LLC","article_published_time":"2025-11-18T04:14:43+00:00","article_modified_time":"2025-12-11T03:04:36+00:00","og_image":[{"width":2560,"height":720,"url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","type":"image\/jpeg"}],"author":"Harald","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Harald","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#article","isPartOf":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/"},"author":{"name":"Harald","@id":"https:\/\/allphasepharma.com\/dir\/#\/schema\/person\/b577474473153b47f4bf5b4cc676a2ee"},"headline":"TACICEPTS VYING FOR YOUR ATTENTION","datePublished":"2025-11-18T04:14:43+00:00","dateModified":"2025-12-11T03:04:36+00:00","mainEntityOfPage":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/"},"wordCount":604,"commentCount":0,"publisher":{"@id":"https:\/\/allphasepharma.com\/dir\/#organization"},"image":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","keywords":["Allphase Pharma Consulting","atacicept","BAFF\/APRIL inhibitors","comparison of Phase 3 trials","competition in IgAN","data cleaning","efficacy comparison of tacicepts","FcRn inhibitors","FDA endpoints","Harald Reinhart","IgA nephropathy","IgAN","ORIGIN trial","povetacicept","proteinuria","telitacicept","UPCR","VERA Pharma","Vertex"],"articleSection":["Recent Literature","The News","The Viewpoint"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","name":"TACICEPTS VYING FOR YOUR ATTENTION - Allphase Pharma Consulting, LLC","isPartOf":{"@id":"https:\/\/allphasepharma.com\/dir\/#website"},"primaryImageOfPage":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#primaryimage"},"image":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","datePublished":"2025-11-18T04:14:43+00:00","dateModified":"2025-12-11T03:04:36+00:00","breadcrumb":{"@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#primaryimage","url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","contentUrl":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","width":2560,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/allphasepharma.com\/dir\/"},{"@type":"ListItem","position":2,"name":"TACICEPTS VYING FOR YOUR ATTENTION"}]},{"@type":"WebSite","@id":"https:\/\/allphasepharma.com\/dir\/#website","url":"https:\/\/allphasepharma.com\/dir\/","name":"Allphase Pharma Consulting, LLC","description":"A Professional Service Provider for the Pharma Industry","publisher":{"@id":"https:\/\/allphasepharma.com\/dir\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/allphasepharma.com\/dir\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/allphasepharma.com\/dir\/#organization","name":"Allphase Pharma Consulting, LLC","url":"https:\/\/allphasepharma.com\/dir\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/allphasepharma.com\/dir\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/LLC-Logo-300x125.jpg?fit=300%2C125&ssl=1","contentUrl":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/LLC-Logo-300x125.jpg?fit=300%2C125&ssl=1","width":300,"height":125,"caption":"Allphase Pharma Consulting, LLC"},"image":{"@id":"https:\/\/allphasepharma.com\/dir\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/allphasepharma.com\/dir\/#\/schema\/person\/b577474473153b47f4bf5b4cc676a2ee","name":"Harald","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cc15d3ef15fa28a3911e16d3eb5c3cdb180799e33fa9a5b7c0ec31faf3a1c1fc?s=96&d=mm&r=g","caption":"Harald"},"sameAs":["http:\/\/www.allphasepharma.com"],"url":"https:\/\/allphasepharma.com\/dir\/author\/haraldeva\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=2560%2C720&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1v5","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":5697,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/03\/5697\/comparison-of-baff-april-inhibitors\/","url_meta":{"origin":5771,"position":0},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS","author":"Harald","date":"November 3, 2025","format":false,"excerpt":"First, a reminder where the name \u2018Berger\u2019s disease\u2019 or Morbus Berger comes from.\u00a0It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients.\u00a0 This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5735,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/08\/5735\/comparison-of-baff-april-inhibitors-2\/","url_meta":{"origin":5771,"position":1},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS \u2013 2","author":"Harald","date":"November 8, 2025","format":false,"excerpt":"Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept.\u00a0 This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] \u00a0We updated our table with this new information that centers on\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":4416,"url":"https:\/\/allphasepharma.com\/dir\/2025\/05\/30\/4416\/baff-april-inhibitors-homing-in-on-igan\/","url_meta":{"origin":5771,"position":2},"title":"BAFF \/ APRIL Inhibitors Homing in on IgAN","author":"Harald","date":"May 30, 2025","format":false,"excerpt":"Today we discuss the group of BAFF\/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":6362,"url":"https:\/\/allphasepharma.com\/dir\/2026\/03\/31\/6362\/igan-therapeutics-the-race-is-on\/","url_meta":{"origin":5771,"position":3},"title":"IgAN Therapeutics – The Race is On","author":"Harald","date":"March 31, 2026","format":false,"excerpt":"Is there a new trend in the journal world: \u00a0publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month 'interim' data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months,\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5632,"url":"https:\/\/allphasepharma.com\/dir\/2025\/10\/20\/5632\/telitacicept-in-sle\/","url_meta":{"origin":5771,"position":4},"title":"TELITACICEPT IN SLE","author":"Harald","date":"October 20, 2025","format":false,"excerpt":"In today\u2019s blog we will share our thoughts about a recent NEJM article, entitled \u201cA Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus\u201d.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not an easy Sunday reads.\u00a0 Of course, there is extensive literature\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/Telitaci-graph-e1760996972139.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":2328,"url":"https:\/\/allphasepharma.com\/dir\/2016\/02\/26\/2328\/brincidofovir-another-drug-fails-in-phase-3\/","url_meta":{"origin":5771,"position":5},"title":"Brincidofovir \u2013 Another Drug Fails in Phase 3","author":"Harald","date":"February 26, 2016","format":false,"excerpt":"It is sad to see a pivotal trial fail, and you have to wonder why we recently had several such late-stage \u2018mishaps\u2019. Take Tetraphase\u2019s eravacycline which failed in a Phase 3 cUTI trial. We have analyzed this drug's failure in\u00a0earlier blogs; there is reason to believe that inadequate dosing was\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"Chimerix - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Chimerix-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=5771"}],"version-history":[{"count":15,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5771\/revisions"}],"predecessor-version":[{"id":5928,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/5771\/revisions\/5928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/5781"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=5771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=5771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=5771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}